BioTelemetry (NASDAQ:BEAT) Director Ronald Ahrens acquired 6,000 shares of the company’s stock on the open market in a transaction dated Friday, May 9th. The stock was purchased at an average price of $7.37 per share, with a total value of $44,220.00. Following the completion of the acquisition, the director now directly owns 187,629 shares of the company’s stock, valued at approximately $1,382,826. BioTelemetry, Inc. (NASDAQ:BEAT) stock opened today at $7.09 and is currently trading at $7.44. The stock showed a negative weekly performance of -19.05%.
Industrial distributor DXP Enterprises Inc. (NASDAQ:DXPE), Houston, TX, reported sales for the first quarter of $348.5 million, an increase of 20.1 percent year-over-year. Organic sales were up 1.7 percent. Profit decreased 12.2 percent to $11.6 million. DXP Enterprises Inc. (NASDAQ:DXPE) stock opened at $67.15, in current trading session and currently is at $68.02, by gaining 2.86%. The 52 week range of $57.00 – $116.88. Company’s market capitalization is 988.99 million.
GasLog Ltd. and its subsidiaries (NYSE:GLOG), an international owner, operator and manager of liquefied natural gas (“LNG”) carriers, reported its financial results for the quarter ended March 31, 2014. EBITDA(1) of $31.1 million (Q1 2013: $13.9 million), earnings per share (“EPS”) of $0.09 (Q1 2013: $0.09) and Profit of $6.3 million (Q1 2013: $5.9 million) for the first quarter. GasLog Ltd (NYSE:GLOG) stock is currently trading at $25.36. The EPS of the stock is 0.90. Company’s market capitalization is 2.05 billion.
Sears Holdings Corp (NASDAQ:SHLD) said it was looking to sell its 51 percent stake in Sears Canada Inc (SCC.TO) in a process that could result in all of the struggling Canadian department store operator being put up for sale. Sears Holdings Corp (NASDAQ:SHLD) stock opened the session at $43.19, and now is at $44.19. The 52 week range of the Sears Holdings Corp (NASDAQ:SHLD) stock remained $31.26 – $67.50 and the day range was $43.18 – $45.00.
Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) agreed to acquire the U.S. rights to a migraine treatment from GlaxoSmithKline PLC (GSK) for $250 million. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock opened today at $6.05 and is currently trading at $5.56. The stock showed a positive weekly performance of 0.94%.